Anti-.alpha.v.beta.3 recombinant human antibodies, nucleic acids encoding same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 8, 2003
Grant Date -
Aug 23, 2001
app pub date -
Jan 30, 1997
filing date -
Jan 30, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to .alpha..sub.v.beta..sub.3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully